Asset / Drug

NHLBI

Drug and asset intelligence for NHLBI with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Sponsor company

ClinicalJune 29, 2026

The NHLBI is conducting a trial to evaluate the efficacy of 18F-FAPI-74 PET/CT imaging in detecting early-stage fibrosis in heart and lung diseases.

ClinicalJune 29, 2026

The NHLBI has initiated a long-term study to monitor the progression of CADASIL in affected individuals and healthy volunteers.

No catalysts indexed for this entity yet.

Topline Data

Monitor trial outcomes, particularly the effectiveness of 18F-FAPI-74 in detecting fibrosis compared to existing imaging modalities.

June 29, 2026 · N/A

Topline Data

Monitor results from the study visits and any findings related to disease progression and vascular health over the 9-year period.

June 29, 2026 · N/A

No related entities indexed yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.